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DOI 10.1016/j.ccr.2012.01.010SUMMARYSynovial sarcoma is a translocation-associated sarcoma where the underlying chromosomal event
generates SS18-SSX fusion transcripts. In vitro and in vivo studies have shown that the SS18-SSX fusion
oncoprotein is both necessary and sufficient to support tumorigenesis; however, its mechanism of action
remains poorly defined. We have purified a core SS18-SSX complex and discovered that SS18-SSX serves
as a bridge between activating transcription factor 2 (ATF2) and transducin-like enhancer of split 1 (TLE1),
resulting in repression of ATF2 target genes. Disruption of these components by siRNA knockdown or treat-
ment with HDAC inhibitors rescues target gene expression, leading to growth suppression and apoptosis.
Together, these studies define a fundamental role for aberrant ATF2 transcriptional dysregulation in the
etiology of synovial sarcoma.INTRODUCTION
Synovial sarcoma is an aggressive soft tissue tumor of adoles-
cents and young adults (Haldar et al., 2008). Histologically, these
tumors can display monophasic (spindle-shaped mesenchymal
cells), biphasic (similar but with focal epithelial differentiation),
or poorly differentiated (small blue round cells generic with
some other translocation-associated sarcomas) morphology.
Treatment consists of wide local tumor excision and radiation,
which cures local disease. Metastatic disease is usually fatal
despite treatment with conventional chemotherapy agents
such as doxorubicin and ifosfamide, which confer at best
a temporary response.
Almost all synovial sarcomas carry a demonstrable, pathogno-
monic t(X;18) reciprocal translocation fusing SS18 to an SSX
gene. Clinical diagnosis can be molecularly confirmed by theSignificance
Synovial sarcoma is a cancer of adolescents and young adult
and metastatic disease is usually fatal. Preclinical studies have
uated in clinical trials. However, the mechanistic basis of SS18
synovial sarcoma has not been defined. Herein, we identify AT
HDAC inhibitors reverse the epigenetic repressor activity of the
ment. These findings thus uncover a role for HDAC inhibitors
concurrent investigations on other types of translocation-assoidentification of this event by karyotyping, RT-PCR, or FISH
techniques, although recently, transducin-like enhancer of split
1 (TLE1) has emerged as a useful immunohistochemical marker
that may obviate the need to resort to molecular testing (Jagdis
et al., 2009). A variety of studies have shown that the resulting
SS18-SSX fusion functions as an oncoprotein; heterologous
expression induces transformation of rat fibroblasts, and
continued expression is needed for tumor cell survival (Nagai
et al., 2001). Most convincingly, in transgenic mice conditional
overexpression of SS18-SSX2 in the myogenic progenitor
compartment, but not other compartments, leads to the appear-
ance of both monophasic and biphasic synovial sarcoma
tumors with full penetrance (Haldar et al., 2007). Together, these
studies indicate that the SS18-SSX fusion protein exhibits
oncogenic activity and is both necessary and sufficient for
tumorigenesis.s for which conventional chemotherapy has limited benefit,
shown sensitivity to HDAC inhibitors, which are being eval-
-SSX-mediated tumorigenesis and HDAC inhibitor action in
F2 as the DNA-binding partner of SS18-SSX and show that
SS18-SSX oncoprotein complex by preventing TLE1 recruit-
in fusion oncoprotein complex assembly, and may inform
ciated cancer.
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Figure 1. SS18-SSX Associates with ATF2 and TLE1 in Synovial Sarcoma
(A) Coomassie-stained gel of the SS18-SSX complex in SYO-1 cells. ATF2 and TLE1 were identified by mass spectrometry. Asterisk indicates IgG bands.
(B) Western blot analysis of the SS18-SSX precipitates (in the presence or absence of EtBr) in SYO-1 cells. Rabbit IgG was used as a negative control.
(C) Reciprocal IP of SS18-SSX, ATF2, and TLE1 showing their interactions in human and mouse synovial sarcoma (SS) tumors.
(D) Glycerol-gradient fractionation profile of SS18-SSX2, ATF2, and TLE1 in SYO-1 cells.
See also Figure S1.
Cancer Cell
SS18-SSX Complex Contains ATF2 and TLE1The SS18-SSX fusion protein retains a C-terminal repressor
domain from either of two highly similar cancer-testis antigens,
SSX1 or SSX2 (SSX4 has also been reported in rare cases),
which is fused to the N terminus of SS18, a transcriptional coac-
tivator (Ladanyi, 2001). The resulting fusion proteins SS18-SSX1
and SS18-SSX2 have no apparent DNA-binding motif, yet
appear to function predominantly in transcriptional regulation
(Lim et al., 1998). The control of gene expression by SS18-SSX
is believed to involve chromatin remodeling, due to its colocali-
zation with both Trithorax (TrxG) and Polycomb group (PcG)
complexes, maintaining chromatin in a poised bivalent state
(de Bruijn et al., 2006; Lubieniecka et al., 2008; Soulez et al.,
1999). Similar to other sarcoma-associated fusion oncoproteins,
expression of SS18-SSX contributes to aberrant transcriptional
activity and dysregulated gene expression. Because SS18-
SSX itself lacks direct DNA-binding domains or activity, it has334 Cancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc.been challenging to identify target genes or to decipher its
mechanism of action. In this article we explore the mechanism
of SS18-SSX-mediated repression and its connection with the
antitumor action of HDAC inhibitors by identifying the key
constituents of SS18-SSX transcriptional complexes in synovial
sarcoma.
RESULTS
Identification of ATF2 and TLE1 within an SS18-SSX
Complex
To study transcriptional regulation governed by SS18-SSX, we
used a validated antibody (RA2009; see Figure S1A available
online) to isolate endogenous SS18-SSX2 and its interactants
from human synovial sarcoma SYO-1 cells (Figure 1A). Mass
spectroscopy further confirmed the presence of SS18-SSX2
Cancer Cell
SS18-SSX Complex Contains ATF2 and TLE1(Figure S1B) and identified several known cofactors, including
histone deacetylases (Figure S1C). This approach also allowed
us to capture multiple peptides corresponding to two previously
uncharacterized components, activating transcription factor
2 (ATF2) and TLE1 (Figure S1C). Both of these are master tran-
scriptional regulators that are highly conserved across different
species. ATF2 is a DNA-binding protein that recognizes the
cAMP-responsive element (CRE) via its leucine zipper domain
and recruits histone acetyltransferases (HATs) to increase
transcription (Kawasaki et al., 2000). However, the other com-
ponent TLE1 is a Groucho corepressor that usually interacts
with transcriptional activators and functions as a competitive
inhibitor to repress transcription (Ali et al., 2010). TLE1 is known
to be highly expressed in synovial sarcoma (Terry et al., 2007)
and has recently been demonstrated to be a robust diagnostic
marker for synovial sarcoma, although its biological function in
this disease has been unclear (Foo et al., 2011; Jagdis et al.,
2009; Kno¨sel et al., 2010).
To validate the proteomic data, immunoprecipitation (IP) was
performed in two human synovial sarcoma cell lines (SYO-1
and FUJI), and this shows that both ATF2 and TLE1 are specifi-
cally precipitated with anti-SS18-SSX, but not with rabbit IgG
(Figures 1B and S1D). Interaction of SS18-SSX2 with both
ATF2 and TLE1 was preserved in the presence of ethidium
bromide (EtBr, Figure 1B), which suggests that this fusion
oncoprotein complex forms independently of DNA. ATF2 and
TLE1 association with both SS18-SSX1 and SS18-SSX2 fusion
proteins was verified by reciprocal IP using RA2009, ATF2, and
TLE1 antibodies (Figure 1C) using patient primary tumors
confirmed to express SS18-SSX1 and SS18-SSX2 (Figure S1E).
Importantly, we find that the mouse homologs of ATF2 (mATF2)
and TLE1 (mTLE1/Grg1) are also bound to the human fusion
protein in cell cultures derived from tumors from SS18-SSX2
conditional overexpression mice (Figure 1C) (Haldar et al.,
2007). The specificity of ATF2-TLE1 association was confirmed
by reciprocal IP using a clear cell sarcoma cell line (DTC-1)
where, in the absence of the SS18-SSX fusion oncoprotein,
ATF2 and TLE1 no longer coimmunoprecipitated (Figure S1F).
This raised the possibility that SS18-SSX serves as a scaffold
to link ATF2 and TLE1. Indeed, glycerol-gradient fractionation
on human synovial sarcoma SYO-1 cells revealed a coelution
profile of ATF2 and TLE1 with SS18-SSX2 (Figures 1D and
S1G), indicating that ATF2 and TLE1 occur in the same SS18-
SSX complex. We also observed several fundamental chro-
matin-remodeling factors (SMARCA2, HDAC1, and EZH2) in
a major overlapping peak with SS18-SSX2 (Figure S1G).
To obtain further evidence of the observed disease-specific
abnormal association of ATF2 with TLE1, a small interfering
RNA (siRNA)-based method was used to deplete endogenous
SS18-SSX2 and its complex components ATF2 and TLE1 in
human SYO-1 and mouse synovial sarcoma cells (Figures S2A
and S2B), and the consequences of cell survival were assessed.
Similar to SS18-SSX2 knockdown, both ATF2/mATF2 silencing
and TLE1/mTLE1 silencing reduce synovial sarcoma cell growth
(Figures 2A and S2C) and impair the ability of human and mouse
tumor cells to form colonies (Figures 2B and S2D). These knock-
down cells appear to undergo apoptosis because depletion of
either ATF2 or TLE1 induces an enrichment in the Annexin-V+
fraction (Figure 2C) and also stimulates Caspase-3 activation(Figure S2E). Together, these data demonstrate that ATF2
and TLE1 functionally associate with SS18-SSX to form an
endogenous complex in synovial sarcoma important for tumor
cell survival.
Copurification of ATF2 and TLE1 Requires SS18-SSX
To gain molecular insights into SS18-SSX complex assembly,
reciprocal IP was performed on human SYO-1 cells transfected
with nonspecific, SS18-SSX2, ATF2, or TLE1 siRNA. Western
blot analysis shows that ATF2 and TLE1 coimmunoprecipitation
is dependent upon SS18-SSX2 (Figure 3A). By contrast, recruit-
ment of ATF2 and TLE1 to SS18-SSX2 seems to be independent
of each other because depletion of ATF2 (or TLE1) has no sig-
nificant impact on SS18-SSX2 association with TLE1 (or ATF2)
(Figure 3B). To further confirm binding specificity, HEK293 cell
lines stably expressingMyc-tagged SS18,SS18-SSX2, or empty
vector were generated (Figure S3A). Analysis of the anti-Myc-tag
precipitates reveals the coexistence of ATF2 and TLE1 with
recombinant SS18-SSX2 (Figure 3C). The lack of TLE1, but not
ATF2, in the Myc-SS18 precipitates (Figure 3C) indicates that
ATF2 and TLE1 recruitment involves different protein domains
of SS18-SSX2. Reciprocal IP of ATF2 and TLE1 also supports
this concept by showing that their connection depends on the
presence of SS18-SSX2 and does not occur with SS18 alone
(Figures S3B and S3C). Consistent with these data, we find
that compared to control cells, ATF2 and TLE1 migrate as
individual glycerol-gradient peaks in SS18-SSX2-knockdown
cells (Figure 3D), implying that they are not found in a shared
complex in the absence of SS18-SSX. The shared change in
ATF2 and TLE1 distribution in glycerol-gradient sedimentation
was also observed in HEK293 stable cell lines with and without
the fusion oncoprotein (Figure S3D). To address which domains
of SS18-SSX are responsible for ATF2 and TLE1 binding, we
next generated SS18-SSX2 deletion mutants (Figures 3E and
S3E) (Nagai et al., 2001) and performed reciprocal IP using the
antibodies specific to Myc-tag, ATF2, and TLE1 in HEK293 cells.
The results suggest that the N-terminal SNH (SYT N-terminal
homolog) domain is responsible for the interaction of SS18-
SSX2 with ATF2, whereas TLE1 specifically interacts with the
repressor domain (SSXRD) of SS18-SSX2 (Figure 3F). In
aggregate these data further reinforce that S18-SSX fusion on-
coprotein serves as a scaffold protein to bridge the Groucho
corepressor TLE1 to transcription factor ATF2 in synovial
sarcoma (Figure 3G).
SS18-SSX/TLE1 Functions to Repress ATF2 Target
Gene Expression
Recent studies have identified the tumor suppressor Early
Growth Response 1 (EGR1) as a direct target of SS18-SSX
(Lubieniecka et al., 2008). This gene was used to study the
mechanisms underlying SS18-SSX occupancy of its targets.
Chromatin immunoprecipitation (ChIP) with antibodies to ATF2,
TLE1, and SS18-SSX identifies a common occupied DNA region
around 100 bp upstream of the transcription start site of the
human EGR1 locus (Figure 4A). Sequence analysis of this
promoter area reveals a consensus CRE site (50-TCACGTCA-
30), which has been well defined in previous studies as a putative
ATF2-binding element, and is phylogenetically conserved
across diverse species (Faour et al., 2005; Hayakawa et al.,Cancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc. 335
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Figure 2. Disruption of the SS18-SSX Complex Reduces Synovial Sarcoma Cell Growth
(A) The effect of SS18-SSX2, ATF2, and TLE1 knockdown on SYO-1 cell growth. Data represent mean ± SD of three experiments.
(B) Colony formation assays on SYO-1 cells at 8 days after indicated siRNA transfections. Representative images for crystal violet stain, and quantitation of
number of colonies by ImageJ software. The black bars represent the mean.
(C) Flow cytometric analysis of apoptotic SYO-1 cells transfected with indicated siRNA following 72 hr. Percentages of Annexin-V+ cells are shown (n = 3). Bar
charts are mean ± SD.
See also Figure S2.
Cancer Cell
SS18-SSX Complex Contains ATF2 and TLE12004). This indicates that the transcription factor ATF2 may have
a critical role in the recruitment of the SS18-SSX complex to
target promoters. To test this possibility, we first examined
the ATF2 cellular location because ATF2 has been shown to
dynamically shuttle between the nucleus and cytoplasm in
a context-dependent manner (Bhoumik et al., 2008; Liu et al.,
2006; Maekawa et al., 2007). Immunohistochemical and immu-
nofluorescent analysis of ATF2 in patient synovial sarcoma
specimens and SYO-1 cells, respectively, shows that ATF2 is
predominantly located in the nucleus (Figures 4B and 4C).
To examine the transcriptional activity of ATF2, published and
in-house microarray expression profiles of patient specimens
were interrogated (Baird et al., 2005; Nakayama et al., 2010;
Nielsen et al., 2002) for the expression of known ATF2 target
genes. In addition to two known SS18-SSX targets EGR1
and Nuclear Protein 1 (NUPR1, or Candidate of Metastasis 1,
COM1) (Ishida et al., 2007), a set of sevenmore genes (Figure 5A)
was chosen for further investigation because their promoters
contain validated CRE sites for ATF2 binding (Figure S4A)
(Hayakawa et al., 2004). These CRE sites are also conserved
between humans and mice, and their protein products are336 Cancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc.involved in controlling cell cycle, apoptosis, and other cellular
signaling pathways (Lopez-Bergami et al., 2010). To validate
these candidate genes, ChIP was performed on SS18-SSX1-
and SS18-SSX2-positive clinical tumor frozen tissue specimens.
Site-specific quantitative PCR (qPCR) shows that both SS18-
SSX1 and -SSX2 fusion proteins, together with ATF2 and
TLE1, bind to the CRE-containing regions (Figures 5B, 5C,
S4B, and S4C). However, we were unable to detect any nonspe-
cific recruitment of these factors (Figures 5B, 5C, S4B, and S4C),
implying a possible predominant role for the ATF2-binding
element in directing SS18-SSX promoter occupancy. To further
evaluate SS18-SSX DNA-binding activity, nuclear proteins were
extracted from HEK293 stable cell lines with and without the
fusion oncoprotein and incubated with infrared dye-labeled
CRE oligonucleotides. An electrophoretic mobility shift assay
(EMSA) identifies a specific protein-DNA complex, which is
supershifted by the antibody against Myc-tag in Myc-SS18-
SSX2-expressing cells, but not in control cells (Figure 5D).
Consistently, a similar protein-DNA complex is also observed
in human SYO-1 cells where it is supershifted by the antibodies
to SS18-SSX, ATF2, and TLE1 (Figure 5E).
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Figure 3. Molecular Association of SS18-SSX with ATF2 and TLE1
(A) Reciprocal IP of ATF2 and TLE1 in control and SS18-SSX2 knockdown SYO-1 cells. Western blot analysis of whole-cell lysates following SS18-SSX2
knockdown are shown on the left.
(B) Western blot analysis of the extracts of control, ATF2, and TLE1 knockdown SYO-1 cells immunoprecipitated by the anti-SS18-SSX antibody.
(C) Myc IP analysis of HEK293 cells stably expressing empty vector, Myc-tagged WT SS18 or SS18-SSX2.
(D) Sedimentation profile of control and SS18-SSX2 knockdown SYO-1 cell extracts by 10%–40% glycerol gradients.
(E) Schematic representing C-terminal Myc-tagged SS18-SSX2 truncation and deletion constructs. FL, full-length fusion oncoprotein; SNH, SYT N-terminal
homolog; QPGY, glycine-/proline-/glutamine-/tyrosine-domain; SSXRD, SSX repressor domain.
(F) Mapping the interface in SS18-SSX2 for its association with ATF2 and TLE1 by reciprocal IP experiments with the Myc, ATF2, and TLE1 antibodies in HEK293
cells expressing the SS18-SSX2 constructs as described in (E).
(G) Schematic model illustrating the scaffolding role of SS18-SSX in ATF2 and TLE1 association.
See also Figure S3.
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SS18-SSX Complex Contains ATF2 and TLE1To further establish a direct link between ATF2 and recruitment
of SS18-SSX, we used a specific siRNA to reduce the expression
of ATF2 in human SYO-1 cells (Figure S5A). ChIP analyses reveal
that loss of ATF2 significantly compromises the association ofSS18-SSX2 and TLE1 with target gene promoters (Figure 6A).
Furthermore, RT-qPCR analysis shows that transcript abun-
dance of multiple ATF2 targets is increased after depleting
ATF2 or SS18-SSX2 (Figure 6B). Consistent with this, in theCancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc. 337
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Figure 4. ATF2 Is Recruited to the EGR1 Promoter along with TLE1
and SS18-SSX and Is Localized to the Nucleus in Synovial Sarcoma
(A) Binding of SS18-SSX, ATF2, and TLE1 across the human EGR1 locus was
assessed by ChIP and site-specific qPCR. Data shown are the mean ± SD of
three experiments where values are expressed relative to rabbit IgG.
(B) Endogenous ATF2 protein is localized to the nucleus in primary synovial
sarcoma tissues by immunohistochemistry. Malignant peripheral nerve sheath
tumor (MPNST) was used as an ATF2-negative control, and cytoplasmic ATF2
staining is shown in a breast cancer case for comparison.
(C) Immunofluorescence analysis of ATF2 nuclear localization in SYO-1 cells.
Hoechst staining defines the nuclei. The box defines the area that was
expanded and shown in the right panel.
Cancer Cell
SS18-SSX Complex Contains ATF2 and TLE1mouse model of synovial sarcoma, SS18-SSX2 and TLE1
binding to target gene promoters is abrogated after ATF2
depletion (Figures 6C and S5B). Notably, an increased transcript
level of either Egr1 or Atf3 was also observed in mATF2- and
SS18-SSX2-knockdown mouse synovial sarcoma cells (Fig-
ure 6D). To confirm the specificity of this effect, wild-type (WT)338 Cancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc.or dn ATF2 was transfected into HEK293 cells in the presence
or absence of the fusion protein SS18-SSX2. As shown in Fig-
ure S5C, compared with the dn form, overexpression of WT
ATF2 in control cells significantly increases EGR1 and ATF3
transcript levels. However, this effect is no longer observed in
SS18-SSX2-expressing cells, indicating that in the presence of
SS18-SSX2, ATF2 transactivational activity is reduced. In agree-
ment with the RT-qPCR data, transfection of an ATF3 reporter
gene in human SYO-1 cells shows that the promoter activity
for this ATF2 target gene is increased 4-fold after SS18-SSX2
depletion, whereas this stimulation is not seen in a construct
with two point mutations in the CRE site of the ATF3 promoter
(Figure 6E). Thus, these experiments demonstrate that the
SS18-SSX complex occupies ATF2 target genes, and this is
dependent upon its interaction with ATF2.
TLE1 also appears to be a functionally important component
of the SS18-SSX complex (Figures 2A–2C). To assess whether
TLE1 influences SS18-SSX transcriptional activity, TLE1 was
knocked down in synovial sarcoma cells. Unlike ATF2 knock-
down, depletion of TLE1 affects neither SS18-SSX2 nor ATF2
recruitment to target promoters EGR1 and ATF3 (Figure 7A).
However, an appreciable increase in transcript levels for both
tested target genes is detected by RT-qPCR in TLE1 knockdown
cells, compared to control cells (Figure 7B). The specificity of this
effect was further confirmed by showing that TLE1 depletion only
induces EGR1 and ATF3 transcription in HEK293 cells in the
presence of Myc-SS18-SSX2 (Figures S6A and S6B). These
results indicate that SS18-SSX negatively regulates the tran-
scription of its target genes via collaborating with TLE1. To
gain molecular insights into the role of TLE1 in SS18-SSX-
mediated repression, histone modifications were analyzed
because previous work linked SS18-SSX recruitment to histone
H3 lysine 27 trimethylation (H3K27me3), a key mark of gene
repression (Lopez-Bergami et al., 2010). TLE1 knockdown in
SYO-1 cells results in a pronounced reduction in H3K27me3
levels at the same EGR1 and ATF3 promoter regions occupied
by SS18-SSX, whereas the levels of trimethylated histone H3
at lysine 4 (H3K4me3), used as controls, are unchanged (Fig-
ure 7C). Given that H3K27me3 is a hallmark of PcG-dependent
gene silencing (Cao et al., 2002; Mu¨ller et al., 2002), we asked
whether TLE1 serves to link the PcG complex to SS18-SSX,
thereby promoting repression of target genes. TLE1 has previ-
ously been shown to have a close relationship with the catalytic
subunits of the PcG complex (Chen et al., 1999; Dasen et al.,
2001; Higa et al., 2006). To test this directly in synovial sarcoma,
human SYO-1 and primary SS18-SSX2 mouse model tumor
cells were used for reciprocal IP analysis. In both cases, copre-
cipitation of TLE1 leads to enrichment of the PcG component,
enhancer of zeste 2 (EZH2), and its functional cofactor, histone
deacetylase 1 (HDAC1) (Figure S6C). Similar interactions were
obtained with other core PcG subunits, such as the embryonic
ectoderm development (EED) protein and suppressor of zeste
12 homolog (SUZ12) (Figures S6D and S6E). These same
components of the HDAC/PcG complex had also been identified
in mass spectrometric analysis of SS18-SSX2-enriched proteins
(Figure S1C), and not surprisingly, EZH2 interactions are main-
tained in the absence of ATF2 but require TLE1 (Figure 7D).
Consistent with these findings, ChIP analysis demonstrates
that depletion of TLE1 is associated with a concomitant
A B
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Figure 5. SS18-SSX Is Recruited to Genes with an ATF/CRE
(A) Heat map from meta-analysis of Affymetrix HG-U133_Plus_2 arrays, from Gene Expression Omnibus accession numbers GSE21050 (PMID 20581836)
and GSE20196 (PMID: 20975339). Quantile normalized GCRMA expression values are given in log base 2 and calculated relative to the median expression for
each gene.
(B and C) ChIP results of primary synovial sarcoma specimens showing SS18-SSX, ATF2, and TLE1 recruitment to the promoter regions of indicated genes.
(B) and (C) represent synovial sarcomas containing either SS18-SSX1 or SS18-SSX2 fusion oncoproteins, respectively. The ChIP enrichment was normalized to
Rabbit IgG, anti-GFP ChIP was used as the negative control, and ChIP assays were also carried out using non-CRE (NC) containing portions of the respective
gene promoters. Bar charts are mean ± SD.
(D and E) EMSA competition and supershift assays showing SS18-SSX2 DNA-binding activity in HEK293 cell models (D) and SYO-1 cells (E). SS, supershift; SC,
SS18-SSX:CRE complex; FP, free probe.
See also Figure S4.
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SS18-SSX Complex Contains ATF2 and TLE1decrease in HDAC1 and EZH2 occupancy on both EGR1 and
ATF3 target promoter regions (Figure 7E), suggesting that
TLE1 functionally regulates HDAC/PcG recruitment to SS18-SSX target promoters. Reciprocal IP of TLE1, HDAC1, and
EZH2 in normal human and mouse fibroblast cells (CCL153
and NIH/3T3) shows association of these three proteinsCancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc. 339
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Figure 6. ATF2 Is Critical for DNA Binding of the SS18-SSX Complex
(A and C) Binding of SS18-SSX, ATF2, and TLE1 to representative target promoters was determined by ChIP-qPCR in human SYO-1 (A) and mouse SS tumor
cells (C) transfected with control or ATF2/mATF2 siRNA.
(B and D) RT-qPCR analysis of indicated ATF2 target gene expression in human SYO-1 cells (B) and mouse SS tumor cells (D) transfected with control,
ATF2/mATF2, or SS18-SSX2 siRNA. Transcript levels were normalized to 18S rRNA, and depicted as a fold change between control and knockdown cells.
(E) Luciferase reporter assays showing the human ATF3 promoter activity in control and SS18-SSX2 knockdown SYO-1 cells. The reporter constructs weremade
with the WT ATF3 promoter regions with or without indicated base substitutions in the ATF/CRE site.
Bar charts are mean ± SD.
See also Figure S5.
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Figure 7. TLE1 Contributes to SS18-SSX-Mediated Repression
(A, C, and E) ChIP-qPCR analysis of the human EGR1 and ATF3 promoters in control and TLE1 knockdown SYO-1 cells. The GFP antibody was used as
a negative control for ChIP assays. Columns represent mean ± SD (n = 3).
(B) RT-qPCR analysis for human EGR1 and ATF3 gene transcripts in SYO-1 cells before and after TLE1 depletion. Transcript levels were normalized to 18S rRNA,
and depicted as a fold change between control and TLE1 knockdown SYO-1 cells.
(D) SS18-SSX IP assay showing its association with HDAC1 and EZH2 in control, ATF2, and TLE1 knockdown SYO-1 cells. Asterisk indicates IgG bands.
(F) Reciprocal IP with the TLE1, HDAC1, and EZH2 antibodies showing their interaction in normal human (left) and mouse (right) fibroblast cells.
(G) ChIP-qPCR analysis of control and mTLE1 knockdown mouse synovial sarcoma cells using the indicated antibodies.
(H) Association of SS18-SSX2 with HDAC1 and EZH2 was determined by IP in mouse SS tumor cells transfected with control or mTLE1 siRNA.
(I) RT-qPCR analysis of Egr1 and Atf3 gene transcripts in mouse tumor cells transfected with control or mTLE1 siRNA for 48 hr. Changes in expression were
normalized to control cells.
Columns represent mean ± SD (n = 3). Bar charts are mean ± SD.
See also Figure S6.
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SS18-SSX Complex Contains ATF2 and TLE1(Figure 7F), and also raises the possibility that TLE1-containing
complexes are shared between cancerous and normal cells. In
accordance with observations in human tumor cells, TLE1 also
has a critical role in assembling HDAC1 and EZH2 into the
SS18-SSX complex and maintaining H3K27me3 levels andtranscriptional repression on the SS18-SSX-bound promoter
regions in the mouse synovial sarcoma model (Figures 7G–7I
and S6F). Taken together, these results indicate that TLE1 is
responsible for SS18-SSX-mediated gene silencing by an
HDAC/PcG-directed epigenetic mechanism.Cancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc. 341
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Figure 8. Effect of HDAC Inhibitors on TLE1 Recruitment and SS18-SSX-Mediated Gene Silencing
(A) RT-qPCR analysis of human EGR1 and ATF3 gene transcripts in SYO-1 cells treated with DMSO, romidepsin, or SB939 for 8 hr. Changes in expression
were normalized to the 0 hr time point.
(B and E) ChIP-qPCR analysis of the EGR1 and ATF3 promoters in SYO-1 and mouse synovial sarcoma cells treated with DMSO, romidepsin, or SB939 for 8 hr.
The antibodies used in ChIP assays are shown at the bottom of each panel.
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SS18-SSX Complex Contains ATF2 and TLE1HDAC Inhibitors Impact SS18-SSX Target Gene
Expression through Modulation of TLE1 Complex
Recruitment
The involvement of HDAC/PcG components in the repressor
activity of the SS18-SSX complex suggests that HDAC or PcG
proteins could be therapeutic targets for the treatment of syno-
vial sarcoma. Indeed, it has been shown that repression of
HDAC activity by small molecule inhibitors can effectively
suppress synovial sarcoma by reversing SS18-SSX-mediated
epigenetic silencing (Lubieniecka et al., 2008; Su et al., 2010).
To further examine the importance of HDAC proteins in regu-
lating SS18-SSX activity, HDAC1 (identified as a core SS18-
SSX complex subunit, Figure S1C) was knocked down. Similar
to the published effects of HDAC inhibitors, depletion of
HDAC1 from SYO-1 cells results in EGR1 reactivation (Fig-
ure S7A), and is also associated with decreased cell growth
and increased cell death (Figures S7B and S7C). Transcript
levels for the SS18-SSX target genes EGR1 and ATF3, as well
as other identified targets, increase following addition of romi-
depsin or SB939 (clinical-grade HDAC inhibitors) (Figures 8A
and S7D). H3K27me3 repressive marks are decreased on the
EGR1 and ATF3 promoters during HDAC inhibitor treatment
(Figure 8B). Further analysis under the same conditions reveals
a concomitant reduction in localization of HDAC1 and EZH2 to
these ATF2 target promoters, even though their protein levels
are unaffected (Figures 8B and S7E). Consistent with this obser-
vation, HDAC inhibitor treatment of SYO-1 cells reduces HDAC1
and EZH2 appearance in the SS18-SSX complex (Figure 8C).
Interestingly, HDAC1 and EZH2 remain bound to TLE1 before
and after exposure to romidepsin (Figure S7F). As noted above,
HDAC/PcG components are recruited to SS18-SSX through
TLE1 (Figures 7D and 7E), and we thus hypothesized that
HDAC inhibitors block HDAC/PcG activity by altering the
behavior of TLE1. In support of this possibility, glycerol-gradient
sedimentation was performed using vehicle (DMSO)- or romi-
depsin-treated SYO-1 cell extracts. Western blot analysis shows
that SS18-SSX2 and TLE1 are located in two separate elution
peaks after HDAC inhibitor treatment, whereas the coelution of
ATF2 with the fusion protein appears to be stable under both
conditions (Figure 8D). To directly test the effect of HDAC inhib-
itors on TLE1 recruitment, the interaction of TLE1with SS18-SSX
was assessed in the presence of romidepsin or SB939 (Fig-
ure 8C). Under these conditions, both HDAC inhibitors block
the association of TLE1 with SS18-SSX and its DNA-binding
partner ATF2. ChIP analysis in HDAC inhibitor-treated SYO-1
cells demonstrates the removal of TLE1 from target promoters,
whereas SS18-SSX2 and ATF2 remain resident (Figure S7G). A
similar abrogation of TLE1, HDAC1, and EZH2 occupancy on
the Egr1 and Atf3 promoters is observed in mouse synovial
sarcoma cells following HDAC inhibitor treatment (Figure 8E).(C) SS18-SSX IP assay in DMSO-, romidepsin-, and SB939-treated SYO-1 ce
of whole-cell lysates (Figure S7E). Asterisk indicates IgG bands.
(D) Glycerol-gradient sedimentation analysis of DMSO- and romidepsin-treated
(F) Transcript levels for Egr1 and Atf3 were measured by RT-qPCR in mouse SS
as a fold change relative to the 0 hr time point.
(G) Model of how the SS18-SSX complex regulates transcription before and afte
Bar charts are mean ± SD.
See also Figure S7.Congruent with this, romidepsin and SB939 induce a time-
dependent increase in the expression of both Egr1 and Atf3 (Fig-
ure 8F), in accordance with a significant decrease in H3K27me3
levels on their promoter regions (Figure 8E). Taken together,
these findings suggest that HDAC inhibitors derepress SS18-
SSX target genes, at least in part through disrupting the recruit-
ment of TLE1 and its associated HDAC/PcG proteins to the
SS18-SSX complex, thus leading to loss of the repressive
H3K27me3 mark and restored gene expression.
DISCUSSION
The nature through which SS18-SSX dysregulates transcription
is a long-standing question in the synovial sarcoma field.
Previous studies have shown that SS18-SSX can interact with
components of the TrxG transcriptional activator complexes
(Nagai et al., 2001; Thaete et al., 1999), as well it has been found
to colocalize with PcG repressor factors (Soulez et al., 1999).
Although these observations suggest a potential role for chro-
matin remodeling in SS18-SSX-mediated gene silencing, it re-
mained unclear how SS18-SSX controls the TrxG-PcG balance
and, more importantly, how this fusion oncoprotein regulates
gene expression in the absence of any known DNA-binding
domain. In this studywe identify a core SS18-SSX transcriptional
complex that is required for epigenetic silencing of tumor
suppressor genes in synovial sarcoma. For assembly of this
complex, the SS18-SSX fusion oncoprotein serves as a scaf-
folding protein to connect together two important transcriptional
regulators: ATF2 and TLE1. SS18-SSX alone cannot bind to
DNA, and its recruitment to target promoters is dependent on
the sequence-specific transcriptional activator ATF2. In this
manner, SS18-SSX recruitment of a TLE1-containing repressor
complex functions to silence ATF2 target genes.
Modulation of ATF2 has also been identified in other cancers,
and interestingly, both activation and inhibition of ATF2 have
been linked to tumorigenesis indicating that ATF2 function in
cancer is context dependent (Lopez-Bergami et al., 2010). For
instance in melanoma, activation of ATF2, which is associated
with predominantly nuclear localization, appears to be impor-
tant for tumorigenesis and metastasis. Conversely, in other
cancers, loss or decreased expression of ATF2 is associated
with an increased incidence of tumorigenesis and metastasis
(Maekawa et al., 2007, 2008). Putative ATF2-inactivating muta-
tions in lung cancer have been identified, and in melanoma
increased ATF2 cytoplasmic localization is associated with
reduced tumorigenic potential and a better prognosis (Berger
et al., 2003; Woo et al., 2002). Atf2 heterozygous mice exhibit
an increased incidence of breast cancer after a long latency
period (>60 weeks), suggesting that an additional hit(s) is
required for tumor progression in this background (Maekawalls. ATF2 and TLE1 protein levels were determined by western blot analysis
SYO-1 cell extracts 8 hr following treatment.
tumor cells treated with DMSO, romidepsin, or SB939 for 8 hr, and depicted
r HDAC inhibitor treatment.
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SS18-SSX Complex Contains ATF2 and TLE1et al., 2007). However, this second hit may in part involve loss of
ATF2 because in all tumors examined ATF2 was undetectable.
In a skin cancer model in mice, deletion of Atf2 was sufficient
to increase the appearance of precancerous lesions (Bhoumik
et al., 2008). However, in this model loss of ATF2 appears to
promote tumorigenesis and is unlikely involved in initiation.
Together, these studies support a fundamental role for ATF2
in tumorigenesis, and highlight the varied mechanisms em-
ployed to inactivate its function.
In synovial sarcoma, ATF2 function is disrupted through
a mechanism in which the fusion oncoprotein couples ATF2 to
a TLE1-containing complex. Interestingly, whereas ATF2 shows
predominantly nuclear localization, the presence of the fusion
oncoprotein in turn leads to repression of ATF2 target genes.
Repression of ATF2 targets is observed in both synovial
sarcoma-derived cell lines and in primary tumors. Furthermore,
restoration of ATF2 transcriptional activity and/or the expression
of some ATF2 target genes leads to growth suppression and
apoptosis in synovial sarcoma cells, indicating that loss of
ATF2 function is important for the maintenance of the tumor
cell phenotype. Importantly, loss of TLE1 phenocopies loss of
ATF2, and leads to upregulation of several ATF2 target genes.
In this regard, TLE1 appears to function in a dn manner on
ATF2-mediated transactivation, by mediating HDAC/PcG-
directed gene silencing of ATF2 targets. It should be noted that
TLE1 expression is an important clinical feature for distinguishing
synovial sarcoma from other soft tissue tumors (Jagdis et al.,
2009; Kno¨sel et al., 2010; Terry et al., 2007). However, the rele-
vance of TLE1 as a specific biomarker for this disease remains
controversial (Foo et al., 2011; Kosemehmetoglu et al., 2009),
in part due to an absence of supportive functional data. Herein,
we define a fundamental role for TLE1 in the etiology of synovial
sarcoma and provide a biological rationale for its use as a diag-
nostic biomarker and potential therapeutic target in synovial
sarcoma.
Synovial sarcomas have been shown to be highly sensitive to
HDAC inhibitors in preclinical models (Ito et al., 2005; Liu et al.,
2008), and herein, we find that the interaction between SS18-
SSX and TLE1 is critical in regulating the epigenetic reprogram-
ming that occurs following HDAC inhibitor treatment. Based on
these findings, we propose a model (Figure 8G) wherein HDAC
inhibitors relieve SS18-SSX-mediated repression at ATF2 target
genes most likely through removal of TLE1 and its associated
HDAC/PcG factors from SS18-SSX. Consequently, as was
also observed with TLE1 knockdown, HDAC/PcG complexes
are no longer recruited to ATF2 target promoters. In support of
this concept, TLE1 depletion similarly results in diminished
H3K27me3 signals and elevated transcript levels for ATF2/
SS18-SSX target genes. The mechanisms underlying HDAC
inhibitor-induced disruption of SS18-SSX-TLE1 interaction are
currently unknown but are being investigated. In summary our
findings provide fundamental insights into the nature of the
SS18-SSX transcriptional complex, including a DNA-binding
partner protein (ATF2) and abnormal recruitment of enzymatic
epigenetic corepressors via TLE1. This information provides
a biological rationale for including synovial sarcoma in clinical
trials of HDAC inhibitors (NCT01112384, NCT00918489,
NCT00878800) and a framework for identifying therapeutic
strategies to treat this deadly disease.344 Cancer Cell 21, 333–347, March 20, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Cells, Tissues, and Chemicals
Human synovial sarcoma cell lines SYO-1 and FUJI were kindly provided
by Dr. Akira Kawai (National Cancer Centre Hospital, Tokyo) and Dr. Kazuo
Nagashima (Hokkaido University School of Medicine, Sapporo, Japan)
and maintained in RPMI-640 medium with 10% fetal bovine serum (FBS)
(Invitrogen). HEK293 cells stably expressing Myc-tagged SS18 or SS18-
SSX2 were grown in DMEM with 10% FBS and 400 mg/ml Zeocin (Invitrogen).
Primary mouse synovial sarcoma cells were isolated from tumors of female
Myf5-Cre/SSM2 mice as described previously (Haldar et al., 2007), and
cultured in DMEM with 10% FBS. All cells were maintained at 37C, 95%
humidity, and 5% CO2.
Human subjects in this study provided informed consent for use of tissues
for research purposes following procedures approved by the Clinical Research
Ethics Board of the University of British Columbia (projects H08-0717
‘‘Sarcoma tissue bank’’ and H06-00013 ‘‘Molecular targets for therapy of
sarcoma’’).
HDAC inhibitors romidepsin (FK228, Depsipeptide, or NSC-630176) and
SB939 were obtained from the Developmental Therapeutic Branch of the
National Cancer Institute (Bethesda, MD, USA) and S*BIO (Singapore, Singa-
pore), respectively. DMSO was purchased from Sigma-Aldrich.
Plasmid DNA Constructs
To define the domains within SS18-SSX2 that interact with ATF2 and TLE1,
variants missing the SNH or QPGY domain of SS18 and the SSXRD domain
of SSX2 were generated via gene synthesis (Integrated DNA Technologies
[IDT]) and subcloned as EcoR1-Not1 fragments into the mammalian ex-
pression vector pcDNA4/myc-HisA (Life Technologies). All genes were engi-
neered to remove the stop, allowing readthrough to generate a C-terminal
Myc-6XHis tag.
IP and Western Blots
For IP, cells were washed twice with ice-cold PBS, and incubated with RIPA
buffer (Santa Cruz Biotechnology) for 35 min on ice. Whole-cell lysates were
centrifuged at 4C, at full speed in a microcentrifuge for 15 min, and the super-
natants were mixed with 15 ml of protein A/G agarose beads (Santa Cruz
Biotechnology) for 45 min at 4C for preclearing. For IP, 500 mg of precleared
proteins was incubated with 1.5 mg of indicated antibody at 4C overnight,
followed by the addition of 25 ml of protein A/G agarose beads. After a 3 hr
incubation at 4C, the beads were precipitated, washed once with RIPA buffer
and twice with ice-cold PBS, and boiled in 23 loading dye for 5 min. Samples
were separated by 10%–12% SDS-PAGE and transferred to nitrocellulose
membranes (Bio-Rad Laboratories). Blots were incubated with indicated anti-
bodies (see below for details). Signals were visualized using the Odyssey
Infrared System (LI-COR Biosciences).
Mass Spectrometry
Coomassie blue-stained bands were excised from the gel and reduced with
dithiothreitol (DTT), followed by alkylation with iodoacetamide (IAA). Gel bands
were digested with Trypsin at 37C overnight as described (Shevchenko et al.,
1996). Proteolytically digested peptides were then extracted from the gel
pieces, reconstituted in formic acid (FA), and analyzed on a QStar XL
LC-MS/MS (Applied Biosystems). The MS/MS peaks were submitted to
Mascot and gpmDB for peptide sequence database search (Wong et al.,
2009). Both of these databases were employed to confirm peptide/protein
identification in this study.
Immunofluorescence and Immunohistochemistry
SYO-1 cells were cultured on glass coverslips, fixed with 3:1 acetone-
methanol at 20C for 7 min, and blocked with 5% BSA for 30 min. Cells
were then incubated with a polyclonal ATF2 rabbit antibody (Santa Cruz
Biotechnology) at 4C overnight, followed by three washes with ice-cold
PBS. After incubation with Alexa Fluor-Conjugated anti-Rabbit secondary
antibody (New England Biolabs), the coverslips were mounted in 50% glycerol
and 2% DABCO (Sigma-Aldrich). The cellular localization of ATF2 was
analyzed under a fluorescence microscope (Zeiss).
Cancer Cell
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cancer samples were embedded in paraffin, and stained with the same
ATF2 antibody used in immunofluorescence. All immunostainings were
performed with avidin-biotin-peroxidase complex technique (VECTASTAIN)
in combination with diaminobenzidine (DAB), and counterstained with
hematoxylin and eosin (H&E) on surgical pathology specimens as described
previously (Pacheco et al., 2010; Terry et al., 2007). Negative controls were
carried out with rabbit IgG.
Glycerol-Gradient Sedimentation
Nuclear extracts were prepared from SYO-1 and HEK293 stable cell lines
using the Pierce NE-PER Nuclear Extraction kit. Samples were then subjected
to a 10%–40% glycerol gradient in 4.8 ml buffer (150mMNaCl, 10 mMHEPES
[pH 7.5], 2 mM DTT, 1 mM EDTA, and 0.1% Triton X-100), and centrifuged at
40,000 rpm for 16 hr at 4C in a SW50.1 rotor (Beckman). Fractions (160 ml)
were collected starting from the top of the gradient, followed by SDS-PAGE
and western blot analysis. To determinemolecular weight (mol wt) of fractions,
marker proteins thyroglobulin (mol wt 669 kDa), b-amylase (mol wt 200 kDa),
and BSA (mol wt 66 kDa) were spiked into the gradients and detected using
their respective antibodies.
RNA Interference
The siRNAs specific for ATF2/mATF2, TLE1/mTLE1, and HDAC1 were
purchased from Dharmacon and Santa Cruz Biotechnology, respectively.
Two different SS18-SSX2 siRNAs were synthesized by IDT as described in
previous studies (Garcia et al., 2011; Lubieniecka et al., 2008). At 60% conflu-
ence, cells were transfected with the indicated siRNA using Lipofectamine
RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s
instructions. Except where indicated, lysates or RNA was harvested 48 hr
post-transfection, and used for IP, glycerol gradients, reporter gene assays,
RT-qPCR, and western blots. Knockdown efficiency was determined by
RT-qPCR.
Cell Growth and Colony Formation Assay
To measure cell growth rate, human and mouse synovial sarcoma cells were
cultured at 60% confluence on 48-well plates, and transfected with the
indicated siRNA using Lipofectamine RNAiMAX transfection reagent. At
various times after transfection, cell growth was monitored by MTT assay
(Life Technologies) and normalized to control cells to give relative growth
rate of cells. For colony formation assay, control and knockdown cells were
replated on 6-well plates at a density of 1 3 103 cells per well. After 8 days
of incubation, cells were fixed with 10% formalin and stained with 0.1% crystal
violet, and the colonies counted by using ImageJ software as described
(Junttila et al., 2007).
Cell Death and Apoptosis Assay
Cells were cultured with propidium iodide (PI) at a concentration of 500 ng/ml,
followed by transfection with the indicated siRNA. Cell death was indicated by
PI-positive cells, and visualized under a fluorescence microscope (Zeiss). For
analysis of apoptosis, cells were harvested 72 hr after siRNA transfection, and
suspended in Annexin-V-FITC-PI dye (Invitrogen). After adding Annexin-V
binding buffer, the samples were run through a FACS scan flow cytometer
(Becton Dickinson) as described (Kawase et al., 2009). Summit for MoFlo
Acquisition and Sort Control Software was used to quantify apoptosis
(Annexin-V positive cells).
ChIP
ChIP experiments were performed following the Active Motif protocol as
described (Su et al., 2010). Briefly, 5 3 107 cells or 150 mg synovial sarcoma
tissues were crosslinked with 1% formaldehyde prior to lysis and homogeniza-
tion. Crosslinked DNA was sheared using a Bioruptor-UCD300 sonicator
(Diagenode) for 15 3 25 s pulses (60 s pause between pulses) at 4C. After
centrifugation, the supernatants were precleared with Protein G beads for
30 min at 4C, and incubated with the indicated antibody at 4C overnight.
After 4 hr incubation with Protein G beads, the precipitates were washed
four times with different washing buffers (Active Motif), eluted with 1% SDS,
and incubated at 65C overnight to reverse crosslinking. ChIP-enriched DNA
was purified using the QIAGEN PCR Purification kit, and subjected to SYBRGreen qPCR analysis (Roche) using various primer sets (Supplemental Exper-
imental Procedures).
EMSA
The ATF/CRE probe was purchased from LI-COR, and labeled on the 50 end of
each strand with Infrared Dye-700 nm. The WT and mutant ATF/CRE compet-
itor probes were obtained from Santa Cruz Biotechnology. Binding reactions
were performed in the dark at room temperature for 30 min in 25 ml of EMSA
buffer (250 mM NaCl, 20 mM HEPES [pH 7.9], 2 mM DTT, 20% glycerol,
0.5% Tween 20) as described before (Boyle et al., 2009). Samples were sepa-
rated on 4% polyacrylamide gels (29.2:0.8 acrylamide-bisacrylamide in
100 mM Tris, 100 mM borate, and 10 mM EDTA). The extent of gel shift was
then visualized on the Odyssey Infrared scanner (LI-COR).
Luciferase Reporter Assay
For luciferase reporter assays, transient transfections were performed using
FuGENE 6 transfection reagent (Roche). SYO-1 cells were subcultured in
24-well plates, and transfected with the WT or mutant human ATF3
promoter-firefly luciferase reporter plasmid together with renilla luciferase
expression vector. After 24 hr incubation, the control or SS18-SSX2-specific
siRNA was introduced using Lipofectamine RNAiMAX transfection reagent.
Cells were harvested at 48 hr after siRNA transfection and analyzed using
the Dual-Luciferase Reporter Assay system (Promega). Firefly luciferase was
normalized to renilla luciferase activity to control for differences in transfection
efficiency and to generate relative luciferase activity.
Real-Time qPCR
Total RNA was isolated and then reverse transcribed to cDNA using the
QIAGEN RNeasy Mini kit and the high-capacity cDNA reverse transcription
kit (Applied Biosystems), respectively, as described previously (Su et al.,
2010). TaqMan gene expression assays were performed by using the ABI-
7500 Fast Real-Time PCR System with specific primer/probe sets (Applied
Biosystems). All transcript levels were normalized to 18S ribosomal RNA
(rRNA) expression.
Antibodies
The rabbit polyclonal antibody (RA2009) against SS18-SSX was kindly
provided by Dr. Diederik R.H. de Bruijn (Radbound University Nijmegen
Medical Centre, Nijmegen, The Netherlands). The antibodies for SS18
(H-80), SSX (C-9), ATF2 (C-19), TLE1 (M-101 and N-18), HDAC1 (10E2),
b-Actin (N-21), Caspase-3 (H-277), and EGR1 (588) were purchased from
Santa Cruz Biotechnology. The H3K4me3 (Upstate; 05-745) and H3k27me3
(Upstate; 07-449) antibodies were used for ChIP. For IP and western blots,
we also used the following antibodies: Myc (Cell Signaling; #2278); HDAC1
(Abcam; ab1767); EZH2 (Active Motif; #39639); EED (Abcam; ab4469);
SUZ12 (Abcam; ab12073); Caspase-3 (Cell Signaling; #9668); and GFP (Cell
Signaling; #2555).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2012.01.010.
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